Drug Profile
4D 710
Alternative Names: 4D 710Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator 4D Molecular Therapeutics
- Class Antifibrotics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cystic fibrosis
Most Recent Events
- 23 Jan 2024 US FDA grants Rare Pediatric Disease Designation (RPDD) to 4D 710 for treatment of Cystic fibrosis
- 07 Jun 2023 4D Molecular Therapeutics plans discussions with FDA for the phase I/II AEROW trial pivotal endpoints in Q1 2024
- 07 Jun 2023 Efficacy, adverse events and biomarker data from a phase I/II AEROW trial in Cystic fibrosis released by 4D Molecular Therapeutics